乳腺三维超声能否在新生辅助化疗肿瘤反应评估中替代MRI——RESPONDER试验
单中心前瞻性观察性预试验纳入25例接受新生辅助化疗的浸润性乳腺癌患者,用自动乳腺容积扫描仪(ABVS)三维超声与乳腺MRI对比评估肿瘤反应,Bland-Altman分析显示中期评估最长径差值ICC 0.73、体积差值ICC 0.52,化疗后体积差值ICC 0.98,观察者间及观察者内ICC均为0.88,患者对ABVS满意度93%高于MRI的12%。
要点
- ABVS与MRI在新生辅助化疗中期评估中73%患者达绝对一致,最长径差值ICC 0.73。
- 化疗后评估体积差值ICC 0.98,中期体积差值ICC仅0.52,提示体积测量时机影响一致性。
- ABVS观察者间及观察者内ICC均为0.88,患者满意度ABVS 93%高于MRI 12%。
核心结论
- ABVS与MRI在新生辅助化疗期间评估乳腺癌肿瘤反应呈「良好」相关,观察者间及观察者内一致性「极好」,患者更偏好ABVS,若能由正在进行的前瞻性试验(NTR6799)证实,可考虑作为乳腺MRI的替代。
研究设计与样本
- 单中心、前瞻性观察性预试验,25例接受新生辅助化疗的浸润性乳腺癌患者,ABVS三维超声与乳腺MRI(标准照护)对比评估肿瘤反应。
诊断标准与关键数值
- 中期评估ABVS与MRI最长径差值ICC 0.73(p<0.01),相关性「良好」。
- 中期评估体积差值ICC 0.52(p<0.01),相关性「一般」。
- 化疗后评估体积差值ICC 0.98(p<0.01),相关性「极好」。
- 观察者间及观察者内一致性ICC 0.88(p<0.01),观察者1与观察者2在直径和体积测量的LOA相当。
- 中期评估MRI与ABVS在73%患者中达绝对一致。
临床应用与阅片要点
- ABVS与MRI在新生辅助化疗中期评估中73%患者绝对一致,最长径差值ICC 0.73,可用于治疗中肿瘤反应监测。
- 化疗后体积测量ICC 0.98,但中期体积测量ICC仅0.52,阅片报告体积变化时需注意评估时机对一致性的影响。
- ABVS观察者间及观察者内ICC 0.88,操作可重复性「极好」,支持其作为连续评估工具。
- 患者对ABVS满意度93%高于MRI的12%,作者认为若正在进行的前瞻性试验(NTR6799)证实这些结果,可考虑将ABVS作为乳腺MRI的替代。
局限性
- 原文报告为单中心、前瞻性观察性预试验。
- 基线测量25例、中期评估20例、化疗后评估仅5例。
- 原文结论指出需由正在进行的前瞻性试验(NTR6799)证实这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: Accurate measurement of tumour response during and after neoadjuvant chemotherapy (NAC) is important and may influence treatment decisions in invasive breast cancer patients. Breast MRI forms the gold standard but is more burdensome, time consuming and costly. In this study response measurement was done with 3-D ultrasound by Automated Breast Volume Scanner (ABVS) and compared to breast MRI. Moreover, patient satisfaction with both techniques was compared.
METHODS AND MATERIALS: A single-institution, prospective observational pilot study evaluating tumour response by ABVS in addition to breast MRI (standard care) was performed in 25 invasive breast cancer patients receiving NAC. Tumour response was evaluated comparing longest tumour diameters as well as tumour volumes at predefined time points using Bland-Altman analysis. Volume measurements for breast MRI were obtained using a fully immersive virtual reality system (a Barco I-Space) and V-Scope software. Same software was used to obtain ABVS volume measurements using an in-house developed desktop VR system. Inter- and intra-observer agreement was evaluated by Intraclass Correlation Coefficient (ICC).
RESULTS: Twenty-five patients were eligible for baseline measurement, 20 for a mid-NAC response evaluation, and five for a post-NAC response evaluation. MRI and ABVS showed absolute concordance in 73% of patients for the mid-NAC evaluation, with a 'good' correlation for the difference in longest diameter measurement (ICC 0.73, p < 0.01) as compared to baseline assessment. Concerning difference in volume measurement in the mid-NAC response evaluation showed a 'fair' correlation (ICC 0.52, p < 0.01) and in the post-NAC response evaluation an 'excellent' correlation (ICC 0.98, p < 0.01). 'Excellent' inter- and intra-observer agreement was found (ICC 0.88, p < 0.01) with comparable limits of agreement (LOA) for observer 1 and 2 in both diameter and volume measurement. Patient satisfaction was higher for ABVS compared to breast MRI, 93% versus 12% respectively.
CONCLUSION: ABVS showed 'good' correlation with MRI tumour response evaluation in breast cancer patients during NAC with 'excellent' inter- and intra-observer agreement. ABVS has patients' preference over breast MRI and could be considered as alternative to breast MRI, in case results on an on-going prospective trial confirm these results (NTR6799).
引用
- van Egdom LSE, Lagendijk M, Heijkoop EHM, et al. Three-dimensional ultrasonography of the breast; An adequate replacement for MRI in neoadjuvant chemotherapy tumour response evaluation? - RESPONDER trial. Eur J Radiol. 2018. PMID: 29857873. doi:10.1016/j.ejrad.2018.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。